55 results about "Oculopathy" patented technology

The present invention relates to the Chinese traditional medicine technical field and particularly relates to a Chinese traditional medicine for curing an external oculopathy of eye disease. The present invention conquers the problems of a slow acting, a bad effect and a limited treatment range in the prior art. In order to conquer the problems in the prior art, the present invention provides a following technical proposal, which is a Chinese traditional medicine for curing the external oculopathy of eye disease, comprising an ephedra, a bupleur, a kudzuvine root, a fineleaf schizonepeta, a divaricate saposhnikovia root, a coptis chinensis, a scutellaria, a gentian, a cape jasmine fruit, a clematis, a platycodon root, a gypsum, a common anemarrhena rhizome, a glabrous greenbrier rhizome, arhubarb, a sodium sulfate, a glycyrrhizae, a grassleaf sweetflag rhizome, a Chinese honeylocust spine, a fruit of negundo, an areca seed, a mica schist, a Tianqi powder, a red peony root, a radix angelicae lateralis preparata, a turmeric root tuber, a buddleja officinalis maxim, a chamomile, a pipewort flower, a caltrop, a sea-ear shell, a semen cassiae torae, a testa mungo, a fructus amomi rotundus, a largehead atractylode, a dried tangerine peel, a coix seed, an angelica, a Szechwan lovage rhizome, a dried rehmannia root, a white peony root, a hare deporis etc. The present invention has theadvantages of a prompt acting, an obvious curative effect, a wide treatment range, a good safe reliability and no toxic and side effects.

The invention discloses fusion protein with anti-tumor, anti-inflammation and oculopathy-treatment functions and a preparation method and application thereof, which belong to the technical field of biological pharmacy. Specifically, the invention relates to the fusion protein of an integrin blocking agent, which has the function of inhibiting tumor angiogenesis and has the integrin affinity and the combining capacity. A rigid (R) or flexible (F) linker is adopted to fuse two polypeptides, so as to respectively obtain protein A and protein G, the medicine effect can be increased, the half-life period can be extended, the stability can be enhanced, and the fusion protein has the characteristics of strong action effect, low toxicity and the like and can be used for preventing and treating solid tumors, all kinds of inflammation and angiogenesis oculopathy. The fusion protein structurally comprises two angiogenesis inhibiting polypeptides and the amino acid linker between the two angiogenesis inhibiting polypeptides, and the fusion protein is expressed in colibacillus or eukaryocyte by using a genetic engineering method and is obtained through separation and purification of a GST (Glutathione S Transferase) affinity column.

Short sight, visual fatigue and ischemic ophthalmopathy belong to the cataract diseases of oculopathy and are mostly caused by emotion problems or body fluid loss, blood shortage, weak kidney and liver which lead to the disorder of entrails, no moistening of eyes, blood stasis, etc., thus causing the loss of sight and even other neopathy. The treatment principle is that the traditional Chinese medicine components which can strengthen the liver and the kidney, supplement blood and body fluid, activate blood circulation to dissipate blood stasis, invigorate the spleen, and be beneficial for moistening are selected; the medicinal materials are extracted (63 percent of effective components, 30 percent of film-forming agent and 7 percent of plasticizer) and blended evenly to make the Chinese medicinal plaster with the thickness of 0.08 to 0.12cm and the plaster is then dried at the normal temperature (the temperature is controlled below 40 DEG C), cut and packaged into a finished product. The medicine can be applied to the skin around the eye and be finally acted on the target area in the ocular fundus after being absorbed by capillary vessels of the skin into the blood circulation of the eye.

The present invention provides a Chinese medicine composition for effectively curing ophthalmopathy, in particular, for curing retinopathy due to diabetes and other angiopathy. The invented Chinese medicine composition includes Chinese medicine A and Chinese medicine B. Said Chinese medicine A is made up by using 10 Chinese medicinal materials of forsythia fruit, cirsium, cephalanoplos, ligusticum root, red peony root and others, and Chinese medicine B is made up by using 8 Chinese medicinal materials of white peony root, notoginseng, salvia root, ligusticum root, poria and others. Said invention also provides their application method.

The invention discloses a medicine for treating oculopathy. The medicine comprises the following active pharmaceutical ingredients in parts by weight: 12-17 parts of cassia seed, 12-17 parts of stem of noble dendrobium, 10-15 parts of climbing groundsel herb, 8-13 parts of chrysanthemum, 8-13 parts of feather cockscomb seed and 1-3 parts of borneol. The medicine is obtained by weighing the active pharmaceutical ingredients according to the parts by weight, washing, drying and sterilizing, soaking and decocting the active pharmaceutical ingredients, filtering the decoction, cooling the filtrate and re-sterilizing the filtrate. The medicine provided by the invention has the characteristics of quickness in effect taking, good curative effects and no toxic or side effects. The medicine is clinically used by totally 836 patients and the average cure rate is 91.5%. The medicine is convenient and fast to use.

A Chinese medicine in the form of eyedrops for treating ophthalmopathy, such as cataract, presbyopia, muscae volitantes, xerophthalmia, etc, is prepared from 10 Chinese-medicinal materials including coptis root, ledebouriella root, ash bark, alum, etc through sequentially decocting, filtering, distilling, cooling and sterilizing.

The invention especially relates to a traditional Chinese medicine composition for preventing and treating oculopathy, belonging to the technical field of medicine and health care. The traditional Chinese medicine composition comprises a component A and a component B, wherein the content of the component B is not more than 15% of the total mass of the traditional Chinese medicine composition. Thetraditional Chinese medicine composition provided by the invention can realize simultaneous treatment of principal and subordinate symptoms of various oculopathy, has small toxic and side effect, is safer to use and controllable in quality, conducts protection and physiotherapy effect on eye diseases, and can alleviate asthenopia and prevent or treat pinkeye, cataract, glaucoma, glaucoma, nyctalopia, xerophthalmia and other diseases.

The invention discloses vision-improving chrysanthemum bagged tea which comprises the following raw materials in parts by weight: 2-4 parts of chrysanthemum, 3-8 parts of polygonum cuspidatum leaves, 1.5-5 parts of ampelopsis grossed and 1.5-5 parts of medlar leaves. A preparation method of the bagged tea comprises the following steps: collecting the chrysanthemum in autumn, washing by clear water, and drying at 60 DEG C for later use; collecting the polygonum cuspidatum leaves, the ampelopsis grossed and the tender medlar leaves in spring, washing by the clear water, sterilizing at 100-110 DEG C for 4-6 minutes, and drying at 50 DEG C for later use; weighing the raw materials according to the weight ratio, uniformly mixing, grinding into 5-20-mesh coarse powder, putting 8-15 g of the powder into each filter paper bag, and sealing to obtain the bagged tea as a finished product. The bagged tea is capable of internally nourishing the liver and calming the liver to improve vision and externally dispelling wind and clearing heat to improve vision, has prevention and auxiliary treatment effects on internal and external oculopathy, is simple in preparation method and convenient to use, has the effects of reducing blood pressure and blood fat, protecting the liver and the like after being drunk for a long term, and is safe and free from toxic and side effects.

The invention discloses a traditional Chinese medicine for treating oculopathy, which is mainly suitable for ophthalmological diseases such as conjunctivitis, stye, trachoma, and the like and belongs to the field of medicaments for eyes. The traditional Chinese medicine is prepared by the steps of grinding raw material medicaments in part by weight: 60 parts of calcined calamine, 6 parts of borneol, 5 parts of amber, 5 parts of calcined coral, 1.5 parts of pearl powder, 3 parts of cinnabar, 1.5 parts of musk, 6 parts of borax and 9 parts of bear gall into fine powder and mixing the powder uniformly. A using method of the traditional Chinese medicine comprises the steps of: dipping clean cold water and the medicinal powder with a glass rod, and applying the mixture to canthi for three times a day. The traditional Chinese medicine has the good treatment effects on various phlogistic eye diseases, bloodshot eyes and gall, epiphora induced by wind, nebula and cataract, blepharitis ciliaris and photophobia, and has the advantages of good treatment effect, no toxic or side effect and relapse prevention after treatment.

The invention relates to the application of recombinant human PH20 to preparation of medicines used for treating thyroid-associated oculopathy, especially to the application of recombinant human PH20to preparation of medicines used for treating acute extraocular muscle oedema and chronic extraocular muscle fibrosis caused by thyroid-associated oculopathy, belonging to the field of bio-pharmaceuticals. Experimental results of the invention prove that the extraocular muscle fibroblasts of patients with thyroid-associated oculopathy have the ability of secreting hyaluronic acid, and the recombinant human PH20 can significantly degrade the hyaluronic acid secreted by the fibroblasts; and the recombinant human PH20 can degradehyaluronic acid, solve the problem of edema in an acute phase, and significantly inhibit the proliferation and differentiation of fibroblasts in the presence of the pathogenic factor IGF-1 so as to inhibit fibrosis. The invention provides a novel countermeasure and means for the treatment of thyroid-related oculopathy.

The invention relates to the novel use of human lysozyme, in particular the use of human lysozyme in pharmaceutical industry, specifically the use of human lisozima in preparing ophthalmocace treating medicine, such as epidemic conjunctivitis, opthalmitis, ceratitis, corneal ulcer diseases caused by bacterium, Chlamydia, viruses and drug resistant medicines. The gene recombination lysozyme has rich source, the eye drops prepared thereby are easy to use.

A Chinese medicine for treating cataract is prepared from 18 Chinese-medicinal materials including coptis root, scutellaria root, Chuan-xiong rhizome, Chinese angelica root, etc.

Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention belongs to the technical field of traditional Chinese medicine, and particularly provides traditional Chinese medicinal eye drops for treating eye diseases. The traditional Chinese medicinal eye drops for treating the eye diseases are prepared from the following raw materials in parts by weight: 15 to 20 parts of pearl powder, 5 to 12 parts of fructus viticis, 10 to 15 parts of apricot leaves, 8 to 12 parts of polygonum multiflorum, 11 to 15 parts of medlar, 13 to 24 parts of goldthread, 5 to 10 parts of parmelia saxatilis, 10 to 12 parts of safflower carthamus, 3 to 10 parts of cape jasmine, 12 to 18 parts of cassia occidentalis, 5 to 15 parts of cordyceps sobolifera, 15 to 20 parts of sedum lineare, 12 to 15 parts of elettaria cardamomum, 18 to 20 parts of digitaria sanguinalis, 8 to 15 parts of lance asiabell root, 5 to 12 parts of lily, 8 to 15 parts of honeysuckle, 6 to 14 parts of cortex dictamni, 12 to 18 parts of the root of red-rooted salvia, and 10 to 15 parts of roughhaired holly root. The traditional Chinese medicinal eye drops for treating the eye diseases provided by the invention are good in medicinal cure effect, quick in effect and low in cost, act on eyes directly, do not have a toxic or side effect, and particularly have very remarkable treatment effects on the eye diseases, such as conjunctivitis, hordeolum and trachoma; therefore, the traditional Chinese medicinal eye drops are worth being popularized and applied widely.

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.

The invention relates to a Chinese herbal preparation for treating eye diseases. The Chinese herbal preparation is composed of rhizoma atractylodis, glabrous greenbrier rhizome, rhizoma bolbostemmae, lawn pennywort herbs, bat dung, cortex phellodendri, gentian, polygonatum odoratum, mulberry leaves and borneol. The Chinese herbal preparation method includes placing the components into a meat lucid ganoderma mother liquid for soaking, fishing out the components from the meat lucid ganoderma mother liquid and drying, frying the components to be charcoals, and porphyrizing the fried components to be powders. The Chinese herbal preparation for treating eye diseases is powder, the Chinese herbal preparation is externally used and directly added for three times each day. The Chinese herbal preparation has the advantages that various symptoms of cataract, myopia, presbyopia and the like can be rapidly eliminated, the cure rate is high, the preparation has anti-inflammation and analgesia effects, both manifestation and root causes of diseases can be treated, and simultaneously pains of patients can be remarkably relieved.

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.

The invention discloses a nutritional food for preventing oculopathy and alleviating asthenopia, and a preparation method thereof. The nutritional food is prepared from 100-180mg of soybean vitamin E ultrafine powder, 80-200g of xanthophyll ultrafine powder, 90-210g of blueberry anthocyanidin ultrafine powder, 150-270g of oligosaccharide ultrafine powder, 400-600g of maltodextrin ultrafine powder, 50-300ml of an alcohol solution and 10-50g of stevioside. The preparation method concretely comprises the following steps: fully mixing the vitamin E ultrafine powder with 1 / 3 of the xanthophyll ultrafine powder, completely adding the xanthophyll ultrafine powder mixed vitamin E ultrafine powder, the remaining xanthophyll ultrafine powder, the blueberry anthocyanidin ultrafine powder, the oligosaccharide ultrafine powder and the maltodextrin ultrafine powder into a three dimensional mixing tank, mixing, discharging, mixing the discharged mixture and the alcohol solution through a bath mixing machine, granulating through a granulating machine, pushing the granulated material to an oven, drying, and carrying out tabletting molding through a tablet press. All raw materials of the nutritional food are purely natural, have high purity, and can be eaten by diabetic patients. The raw materials are processed to form the nutritional food, and the nutritional food makes people have no medicine administration feeling and can protect eyes.

A Chinese medicinal eye drop for treating oculopathy is colorless transparent solution prepared by mixing leaching solution and Fel Ursi powder. The leaching solution is prepared from (by weight parts) 3-5 parts of Semen Cassiae, 3-5 parts of Herba Senecionis Scandentis, 1.5-3 parts of Radix Angelicae Sinensis, 1.5-3 parts of Prunellae Spica and 1-4 parts of Herba Chlorophyti by pulverizing and leaching. The leaching solution is subjected to distillation purification and sterilization, mixed with the Fel Ursi powder at ratio of 10 mL:(0.5-1.5) g, and hermetically packaged with plastic bottle.The eye drop is administered at dosage of 1-2 drops / eye for 2-3 times daily. The eye drop has obvious and rapid effects on common oculopathy such as keratitis, muscae volitantes, pterygium, acute hemorrhagic conjunctivitis, epiphora with wind, eye swelling and pain, trachoma, and blur vision, with short treatment course and no toxic side effects.

The present invention is one kind of myopia treating typoscope. The myopia treating typoscope has one lower right outward eye hole corresponding to the right eye and one lower left outward eye hole corresponding to the left eye, and these two eye holes have opposite directions.

Disclosed are an ophthalmic injectable sustained-release formulation, a process for preparing the same and a method for treating and preventing oculopathy with the same. The ophthalmic injectable sustained-release formulation comprises a delivery system and a pharmaceutically acceptable excipient, wherein the delivery system is selected from the group consisting of microspheres, microcapsules, microparticles, liposomes, multivesicular liposomes, nanocrystals and nanoparticles.

The invention relates to a traditional Chinese medicine for treating the oculopathy, which comprises the following main components: selfheal, pipewort, butterflybush flower, seeds of feather cockscomb, rough gentian, oriental wormwood, bupleurum chinense, indigowoad root, fructus forsythiae, radix salviae miltiorrhizae, polygala root, safflower, pangolin scales, angelica, baikal skullcap root and the like. The new medicine can activate the channels and collaterals, can be suitable for various oculopathy, and has low cost and no toxic or side effect; in addition, the effective rate is 90%, and the curative ratio is 85%.

The inventions discloses a novel mouse nerve growth factor intravitreal injection drug delivery system and an application thereof, and relates to the field of mouse nerve growth factor-containing drug for treating oculopathy through intravitreal injection drug delivery. In allusion to the problems that non-ideal treatment effect and big side effects existing in a conventional drug delivery mode of a mouse nerve growth factor for treating oculopathy, the invention aims to provide the mouse nerve growth factor intravitreal injection drug delivery system which is characterized by comprising the mouse nerve growth factor and an ultrasonic contrast agent. The invention also provides the application of the mouse nerve growth factor intravitreal injection drug delivery system in preparing a drug for treating glaucomatous optic nerve damage, wherein the drug is used for being administrated by intravitreal injection under ultrasonic irradiation. The novel drug delivery mode provided by the invention has the advantages of good treatment effect, safety and reliability, and can be used for delaying or preventing occurrence and development of the glaucomatous optic nerve damage.

The invention belongs to the field of Chinese materia medica preparations and particularly provides an oculentum for treating the eye disease. The oculentum is made from 25 parts of evodia lepta, 28 parts of canadian erigeron, 16 parts of cyathula prostrata, 18 parts of roots of common butterbush, 18 parts of coptis chinensis, 25 parts of angelica dahurica, 15 parts of semen cassiae, 25 parts of dandelion, 20 parts of scutellaria baicalensis, 18 parts of folium artemisiae argyi, 15 parts of roots of Chinese pulsatilla, 18 parts of portulaca oleracea and 5 parts of liquorice. The oculentum is made into a medicinal extract and capable of treating the eye disease.

The invention provides a diabetic retinopathy lesion image recognition method based on an attention model, and the method is characterized in that the method comprises the steps: firstly, carrying out the preprocessing suitable for a medical image for an original fundus image in a data set; secondly, constructing an attention network model based on semantic segmentation to perform feature extraction; then, constructing a lesion sensing module, a feature keeping module, a feature fusion module and a head attention module, extracting lesion related information from the extracted features, and generating a lesion detection probability graph; and finally, guiding eye disease screening by using the focus detection probability graph obtained by the attention model according to the input fundus photo, and obtaining a fundus photo recognition result with diabetic retinopathy focus information. According to the method, related focus information in the fundus photo can be effectively obtained, the interpretable focus detection probability graph is generated while the diabetic retinopathy is automatically screened, ophthalmologists can be well assisted in diagnosis, and the method has wide clinical application prospects.

The invention belongs to the technical field of medicament, specifically relates to an eye drop having functions of easing indisposition and weariness of eyes, particularly treating xerophthalmus. The main active ingredient of the formula of the eye drop is carboxymethyl chitosan. The invention has long lasting effect and antibacterial function, thereby bioavailability of medicament is improved.

The present invention relates to the use of puerarin in preparing medicine for treating myopia, and belongs to the field of the medicinal application of puerarin. The medicine of puerarin for treating myopia has the advantages of high curative effect and less side effect.

The invention discloses fusion protein with anti-tumor, anti-inflammation and oculopathy-treatment functions and a preparation method and application thereof, which belong to the technical field of biological pharmacy. Specifically, the invention relates to the fusion protein of an integrin blocking agent, which has the function of inhibiting tumor angiogenesis and has the integrin affinity and the combining capacity. A rigid (R) or flexible (F) linker is adopted to fuse two polypeptides, so as to respectively obtain protein A and protein G, the medicine effect can be increased, the half-life period can be extended, the stability can be enhanced, and the fusion protein has the characteristics of strong action effect, low toxicity and the like and can be used for preventing and treating solid tumors, all kinds of inflammation and angiogenesis oculopathy. The fusion protein structurally comprises two angiogenesis inhibiting polypeptides and the amino acid linker between the two angiogenesis inhibiting polypeptides, and the fusion protein is expressed in colibacillus or eukaryocyte by using a genetic engineering method and is obtained through separation and purification of a GST (Glutathione S Transferase) affinity column.

The invention discloses an aptamer specifically bound with sICAM-1 and a kit. The aptamer and the sICAM-1 have the good affinity. By means of the aptamer, the sICAM-1 in a solution can be captured to be prepared into the corresponding kit for ophthalmopathy screening. The kit has the advantages of being high in sensitivity and low in cost, and is suitable for large-scale screening.

The invention provides a traditional Chinese medicine for treating eye diseases. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight: 18 parts of fructus forsythiae, 22 parts of flos eriocauli, 22 parts of flos buddlejae, 22 parts of radix isatidis, 13 parts of radix salviae miltiorrhizae, 18 parts of pseudo-ginseng, 20 parts of the root bark of the peony tree, 18 parts of dried rehmannia root, 15 parts of ganoderma lucidum, 22 parts of oyster, 28 parts of Longnei, 15 parts of radix bupleuri, 15 parts of herba asari, 15 parts of fructus gardeniae, 25 parts of concha haliotidis, and 15 parts of chrysanthemum flowers. The traditional Chinese medicine is prepared from the pure traditional Chinese medicinal materials, has high curative effects in treating the eye diseases, treats both symptoms and root causes, is obvious in curative effects, is free of untoward effects, and is small in toxic and side effects, the clinical symptoms disappear rapidly, and no relapse phenomenon exists after curing of the eye diseases.